Clinical Research Directory
Browse clinical research sites, groups, and studies.
Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment
Sponsor: St. Petersburg State Pavlov Medical University
Summary
Children with relapsed or refractory Hodgkin lymphoma receive 3-6 cycles of nivolumab monotherapy. In case of achieving complete response (CR) auto-HSCT is performed. In the absence of CR, 3-6 additional cycles of nivolumab with bendamustine are administered. If complete or partial response is achieved, auto-HSCT is performed.
Official title: Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment With or Without Bendamustine
Key Details
Gender
All
Age Range
2 Years - 18 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2022-06-01
Completion Date
2027-06-01
Last Updated
2025-04-17
Healthy Volunteers
No
Conditions
Interventions
Nivolumab
Nivolumab with or without bendamustine is administered to children prior to auto-HSCT
Locations (2)
N. N. Blokhin Russian Cancer Research Center, Moscow, Russia
Moscow, Russia
Pavlov University, RM Gorbacheva Research Institute
Saint Petersburg, Russia